Matthew B. Murphy net worth and biography

Matthew Murphy Biography and Net Worth

General Counsel of Nautilus Biotechnology

Matt has spent over a quarter century advising companies on the cutting edge of life sciences technologies. He has held numerous General Counsel roles over this period, including most notably at Pacific Biosciences and 10X Genomics. He specializes in creating and defending industry defining patent portfolios, and in building and leading legal operations that help develop, finance and commercialize high growth companies. Matt received his Bachelor of Science in Microbiology and Fermentation Science from the University of California, Davis, and a Juris Doctorate from the University of San Francisco School of Law.

What is Matthew B. Murphy's net worth?: The estimated net worth of Matthew B. Murphy is at least $218.71 thousand as of September 4th, 2025. Mr. Murphy owns 74,140 shares of Nautilus Biotechnology stock worth more than $218,713 as of April 11th. This net worth approximation does not reflect any other assets that Mr. Murphy may own. Learn More about Matthew B. Murphy's net worth.
How do I contact Matthew B. Murphy?: The corporate mailing address for Mr. Murphy and other Nautilus Biotechnology executives is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. Nautilus Biotechnology can also be reached via phone at 206-333-2001 and via email at [email protected]. Learn More on Matthew B. Murphy's contact information.
Has Matthew B. Murphy been buying or selling shares of Nautilus Biotechnology?: Matthew B. Murphy has not been actively trading shares of Nautilus Biotechnology during the last quarter. Most recently, on Thursday, September 4th, Matthew B. Murphy bought 20,000 shares of Nautilus Biotechnology stock. The stock was acquired at an average cost of $0.64 per share, with a total value of $12,800.00. Following the completion of the transaction, the general counsel now directly owns 74,140 shares of the company's stock, valued at $47,449.60. Learn More on Matthew B. Murphy's trading history.
Who are Nautilus Biotechnology's active insiders?: Nautilus Biotechnology's insider roster includes Mary Godwin (VP), Parag Mallick (Insider), Matthew Mcilwain (Director), Anna Mowry (CFO), Matthew Murphy (General Counsel), Sujal Patel (CEO), Matthew Posard (Director), and Kentaro Suzuki (CMO). Learn More on Nautilus Biotechnology's active insiders.
Are insiders buying or selling shares of Nautilus Biotechnology?: In the last year, Nautilus Biotechnology insiders bought shares 8 times. They purchased a total of 277,500 shares worth more than $240,250.00. The most recent insider tranaction occured on March, 4th when CEO Sujal M Patel bought 25,000 shares worth more than $65,250.00. Insiders at Nautilus Biotechnology own 41.1% of the company. Learn More about insider trades at Nautilus Biotechnology.
Information on this page was last updated on 3/4/2026.

Matthew B. Murphy Insider Trading History at Nautilus Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/4/2025	Buy	20,000	$0.64	$12,800.00	74,140
8/15/2022	Buy	7,500	$2.84	$21,300.00	54,140
8/12/2022	Buy	2,500	$2.85	$7,125.00	46,640
8/13/2021	Buy	5,000	$7.56	$37,800.00

Matthew B. Murphy Buying and Selling Activity at Nautilus Biotechnology

Nautilus Biotechnology Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Today's Range

Now: $2.95

$2.83

$3.18

50 Day Range

MA: $2.74

$2.01

$3.95

2 Week Range

Now: $2.95

$0.62

$4.31

Volume

392,953 shs

Average Volume

408,241 shs

Market Capitalization

$373.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08